Drug intelligence / Profile preview

fiztasovimab

Development stage: Phase 2
Lead developer: Nobelpharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Fiztasovimab (NPC-21; EV2038) is a fully human monoclonal antibody that targets antigenic domain 1 of glycoprotein B on the human cytomegalovirus (hCMV) envelope. It exhibits broadly neutralizing activity and inhibits cell-to-cell transmission of hCMV. Fiztasovimab is being developed for the prophylactic or preemptive treatment of hCMV infection in patients undergoing solid-organ or hematopoietic stem cell transplantation. The drug has demonstrated safety and tolerability in phase 1 studies and has advanced to phase 2 clinical trials for prevention of cytomegalovirus infections[1][2][3][4].

Other names: fiztasovimabNPC-21NPC21NPC 21EV2038EV-2038EV 2038

Targets

gB (Human cytomegalovirus glycoprotein B)

Beyond the preview

Go deeper on fiztasovimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fiztasovimab.

Explore the full profile